Otros idiomas Cassava Sciences, Inc.

Acciones

SAVA

US14817C1071

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:11:52 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
22,09 ^USD	-0,27 %		+6,51 %	-1,87 %

25/03	Cassava Sciences anuncia la finalización de la revisión provisional de seguridad de su candidato a fármaco contra el Alzheimer, el simufilam	MT
25/03	Cassava Sciences, Inc. anuncia la finalización de una revisión provisional de la seguridad del simufilam oral en ensayos de fase 3 en curso	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	15:10
North American Morning Briefing : Investors Brace -2-	29/04
Cassava Sciences : Corporate Presentation – Second Quarter 2024	24/04
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	16/04
Redemption Date Announced for Warrants	15/04
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	29/03
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	27/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	27/03
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25/03
Cassava Sciences : Corporate Presentation – First Quarter 2024	25/03
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	25/03
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25/03
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	21/03
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	20/03
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	19/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	19/03
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	17/03
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	15/03
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	13/03
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?	13/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cassava Sciences, Inc.

Acciones

SAVA

US14817C1071

Otros idiomas

Filtros